4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Superinvestors holding FDMT, Q2 2026
No superinvestor reported holding FDMT in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of FDMT each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q3 2024
0 superinvestors holding at quarter end
- Sold out
- Viking Global Investors
Q2 2024
1 superinvestor holding at quarter end
- Sold out
- Soros Fund Management
Q1 2024
2 superinvestors holding at quarter end
- New
- Soros Fund Management
- Reduced
- Viking Global Investors (−38.7%)
Q2 2023
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+21.6%)
Q2 2021
1 superinvestor holding at quarter end
- Sold out
- HHLR Advisors (Hillhouse)